Design and optimisation of selective serotonin re-uptake inhibitors with high synthetic accessibility: part 2.
A second wave of potential SSRIs with high ease of synthetic accessibility were designed based on the reported selective serotonin re-uptake inhibitor litoxetine and our own previous work in this area. Preparation and subsequent optimisation yielded a range of potent and highly selective SSRIs.
Andrews
Mark
M
Discovery Chemistry, Pfizer Global Research and Development, Sandwich, United Kingdom.
Brown
Alan
A
Chiva
Jean-Yves
JY
Fradet
David
D
Gordon
David
D
Lansdell
Mark
M
MacKenny
Malcolm
M
D018759:Adrenergic Uptake Inhibitors / Q000737:chemistry / Q000494:pharmacology; D000928:Antidepressive Agents / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D018765:Dopamine Uptake Inhibitors / Q000737:chemistry / Q000494:pharmacology; D015195:Drug Design; D050486:Serotonin Plasma Membrane Transport Proteins / Q000737:chemistry* / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology; D013329:Structure-Activity Relationship
D018759:Adrenergic Uptake Inhibitors; D000928:Antidepressive Agents; D018765:Dopamine Uptake Inhibitors; D050486:Serotonin Plasma Membrane Transport Proteins; D017367:Selective Serotonin Reuptake Inhibitors